市場調查報告書
商品編碼
1447723
抽吸針市場評估:按應用、治療、最終用戶和地區劃分的機會和預測(2017-2031)Aspiration Needles Market Assessment, By Application, By Procedure, By End-user, By Region, Opportunities and Forecast, 2017-2031F |
全球抽吸針市場規模預計將從2023年的9.275億美元成長到2031年的15.4272億美元,2024-2031年預測期間複合年增長率為6.57%,預計規模將會成長。
由於全球癌症盛行率不斷上升,抽吸針市場預計將成長。 隨著癌症患者數量的增加,用於活檢和其他診斷的抽吸針的需求預計將顯著增加。 各國政府和醫療機構正在推動癌症篩檢和診斷,導致活檢針的需求增加。 此外,人們越來越喜歡侵入性較小的診斷方法,這推動了對抽吸針的需求。 此外,快速的技術進步也是主要的成長動力。 創新技術正在提高活檢程序的準確性和效率,從而改善患者的治療效果和更高的採用率,進一步推動市場成長。 然而,與使用抽吸針相關的設計風險和併發症是該市場的主要挑戰。 進入者專注於產品創新和合作夥伴關係,以克服這些挑戰並增加利潤。
癌症病人增加
癌症是全世界死亡的主要原因。 生活方式的改變、菸酒消費以及輻射暴露是癌症的主要原因,導致癌症病例顯著增加。 癌症早期檢測診斷方法的進步正在迅速增加癌症診斷市場的需求。 大多數癌症病例是透過活檢方法診斷的,其中廣泛使用抽吸針。 癌症活檢對於降低死亡率至關重要,這正在推動全球抽吸針市場的擴張。
世界衛生組織 (WHO) 報告稱,2020 年新增癌症病例約為 1,930 萬例,預計到 2025 年這一數字將增至 2,160 萬例。 乳癌是全世界最常見的癌症,過去五年估計有 780 萬名女性死於乳癌。 根據 Globocan 最近的調查數據,乳癌約佔所有癌症病例的 12%。 這種常見疾病可能會在未來幾年推動市場的顯著成長。
對微創診斷的偏好日益增加
人們對微創診斷程序的日益青睞正在推動對抽吸針的需求,以降低發病率、死亡率、住院時間和成本。 微創手術,例如由影像技術引導的手術,允許醫生透過針刺或導管治療症狀,從而減少開放手術的需要。 這些手術越來越多地被用作一種治療方式,改善患者的治療效果,並為不適合傳統開放性手術的患者提供更多的治療選擇。 2023 年 10 月,Praxis Medical 的 EndoCore 經支氣管針吸活檢 (EBUS-TBNA) 微針活檢技術獲得 FDA 510(k) 許可。 EndoCore EBUS-TBNA活檢裝置由美國一家醫療器材公司開發,用於輔助肺癌的診斷和分期。
在癌症應用的優勢
細針穿刺切片(FNA)廣泛應用於乳癌、肺癌、大腸癌、攝護腺癌、腎癌、骨及骨髓癌等的診斷。 FNA 被認為是一種優秀、安全且具有成本效益的診斷方法,特別是在乳房腫塊的評估方面。 此外,FNA 非常準確,對某些類型的癌症的敏感性超過 90%,特異性超過 95%。 公司正在積極致力於開發解決方案並獲得監管部門的批准。
本報告調查了全球抽吸針市場,提供了市場定義和概述、市場規模趨勢和預測、各個細分市場和地區的詳細分析、行業結構以及影響市場成長的因素分析、案例研究、競爭格局、主要公司的簡介等等。
Global aspiration needles market is projected to witness a CAGR of 6.57% during the forecast period 2024-2031, growing from USD 927.5 million in 2023 to USD 1542.72 million in 2031. The aspiration needle market is anticipated to thrive due to the growing prevalence of cancer across the globe. With the growing number of cancer cases, the demand for aspiration needles for biopsy and other diagnostics is expected to increase significantly. Governments and health organizations promote cancer screenings and diagnostics, contributing to an increase in demand for biopsy needles. There is a growing preference for minimally invasive diagnostic procedures, which drives demand for aspiration needles. Moreover, rapid technological advancements represent a significant growth-inducing factor. Innovative technologies enable better accuracy and efficiency in biopsy procedures, leading to improved patient outcomes and increased adoption rates, further boosting the market growth. However, risks associated with the use of aspiration needles and design complications are some major challenges for this market. Market players are focusing on product innovations and partnerships to overcome these challenges and drive profits.
In September 2023, Broncus Medical launched the BioStar Transbronchial Aspiration Needle (TBNA) to facilitate minimally invasive diagnostic procedures. This advanced needle enables medical professionals to collect precise tissue samples and high-quality specimens, aiding in the diagnosis and staging of lung cancer. The needle seamlessly integrates with endobronchial ultrasound bronchoscopy (EBUS) techniques, enhancing clinical outcomes and patient care. Designed for versatility, the BioStar TBNA is suitable for both conventional TBNA (cTBNA) and EBUS-TBNA diagnostic methods. Broncus offers the needle in 21G, 22G, and 25G sizes to accommodate various clinical needs.
Increasing Number of Cancer Cases
Cancer is a primary cause of death worldwide. Changes in lifestyle, tobacco and alcohol consumption, and radiation exposure are leading causes of cancer and have resulted in a significant increase in cancer cases. Advancements in diagnostics for early cancer detection have surged the demand in the cancer diagnostics market. The majority of cancer cases are diagnosed through the biopsy method and aspiration needles are widely used for that purpose. Cancer biopsy is essential to lower mortality rates, thereby driving the global aspiration needle market's expansion.
The World Health Organization reported approximately 19.3 million new cancer cases in 2020, a number that is projected to rise to 21.6 million by 2025. Breast cancer is the most common cancer globally, with an estimated 7.8 million women surviving breast cancer in the past five years. Data from recent Globocan study indicates that breast cancer accounts for roughly 12% of all cancer cases. This prevalent condition is likely to drive significant market growth over the forthcoming years.
Growing Preference for Minimally Invasive Diagnostic Procedures
The growing preference for minimally invasive diagnostic procedures is driving the demand for aspiration needles due to the benefits they offer in terms of decreased morbidity, mortality, hospitalization time, and expenses. Minimally invasive procedures, such as those guided by imaging technologies, allow physicians to treat conditions through needle punctures or catheters, reducing the need for open surgeries. These procedures are increasingly being used in therapeutic modalities, leading to improved patient outcomes, and expanded treatment options for individuals who are not candidates for traditional open surgeries. Manufacturers are actively involved in product development to cater to the market needs. For example, in October 2023, Praxis Medical received FDA 510(k) clearance for its EndoCore Endobronchial ultrasound with transbronchial needle aspiration (EBUS-TBNA) tiny needle biopsy technology. The EndoCore EBUS-TBNA biopsy instrument was created by an American medical device business to aid in the diagnosis and staging of lung cancer.
Dominance of Cancer Application
Fine-needle aspiration (FNA) is widely used in the diagnosis of breast cancer, lung cancer, and other types of cancer, such as colorectal, prostate, kidney, and bone and bone marrow cancer. FNA is considered an excellent, safe, and cost-effective diagnostic procedure, particularly for evaluating breast lumps. Additionally, FNA is highly accurate, with sensitivities above 90% and specificities above 95% for certain types of cancer. Market players are actively involved in developing solutions and obtaining regulatory clearance. For instance, in September 2023, Limaca Medical obtained approval from the FDA for its innovative Precision GI, a first-of-its-kind endoscopic biopsy tool for gastrointestinal diseases. Unlike other existing biopsy devices, Precision GI uses an automated, motorized cutting needle, ensuring precise tissue collection for accurate diagnosis. Limaca Medical, a leading healthcare company, is committed to revolutionizing endoscopic biopsy procedures for patients battling life-threatening digestive and lung cancers.
Image-guided Systems Dominate the Market
Image-guided systems are preferred for aspiration needle biopsies due to their higher accuracy compared to palpation-guided biopsies. Research shows that image-guided biopsies have a sensitivity of 96.3% for diagnosing malignant lesions, while palpation-guided biopsies have a lower sensitivity of 46.7%. Image guidance, such as ultrasound, allows for real-time visualization of the needle placement, ensuring accurate sampling of the target tissue. Additionally, image-guided biopsies offer advantages like better patient tolerance, improved cosmetic outcomes, and cost-effectiveness compared to open surgical biopsies. The use of image guidance in needle biopsies improves diagnostic accuracy and minimizes the risk of erroneous sampling, making it the preferred choice for various medical procedures.
In February 2023, TransMed7, a company specializing in breast biopsy devices, announced the clinical use of production models of its Concorde US ultrasound-guided biopsy devices. The Concorde US platform consists of two models, the Concorde US model and Concorde ST. Among these, Concorde US can be used handheld with ultrasound guidance or with an optional stage mount adapter for stereotactic and 2D/3D tomosynthesis procedures. On the other hand, Concorde ST is suitable for stereotactic and 2D/3D tomosynthesis-guided breast biopsy procedures, offering console-replacing functionality.
North America to be the Dominating Region
North America dominates the aspiration needle market due to several reasons. Firstly, there is a well-developed healthcare infrastructure in the region, which supports the adoption of advanced medical technologies such as aspiration needles. Secondly, there is high healthcare spending in countries like the United States, which drives the demand for innovative medical devices. Thirdly, there is an increasing prevalence of chronic diseases, which require regular monitoring and treatment using aspiration needles. Finally, there is a strong focus on improving the visibility of biopsy needles to aid market growth, which contributes to the dominant position of North America in the aspiration needle market.
Future Market Scenario
Over time, transthoracic needle aspiration (TTNA) has undergone major advancements, and continuing developments promise to improve its efficiency and introduce individualized medicine. Technology advancements, better biopsy samples, and increased capabilities are among these advancements. TTNA has moved from fluoroscopy to computed tomography (CT), resulting in better visualization and cutting-edge biopsy equipment. In TTNA operations, a variety of needles are utilized, including suction needles, cutting needles, and automated core biopsy needles. The future holds promising growth for the aspiration needles market.
Key Players Landscape and Outlook
Merit Medical Systems, Cook Group Incorporated, Olympus Corporation, Medtronic PLC, Argon Medical Devices Inc., and Boston Scientific Corporation are some of the key players in the aspiration needles market. These companies are major players in the industry, focusing on strategies like product launches, technological innovations, and partnerships to strengthen their market position. Market tactics like mergers and acquisitions are some other factors driving the market growth.
In November 2023, Broncus, through its Chinese subsidiary, agreed to purchase 100% of Hangzhou Jingliang, a Chinese device manufacturer. This acquisition aims to expand Broncus's offerings in lung disease diagnosis and treatment, including the BioStar transbronchial aspiration needle (TBNA) for minimally invasive diagnostic applications. China represents a significant market for Broncus, contributing USD 4.25 million in revenue during the first half of the fiscal year 2023.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.